Professor Rolf Marshallek from the University of Goethe in Germany led the research on the subject Rare Side Effects, which led, among other things, to the development of the AstraZeneca vaccine Taken from the Norwegian vaccination program.
AstraZeneca and Janssen both use vector technology in their vaccines.
When the virus (vector) enters the cells of the body, the cells of the body will use the information to produce the spike protein on the coronavirus, against which the body makes antibodies.
Coronavirus: Spiky protein is often portrayed as the virus’s red flags. Photo: NIH Bulletin
–
Marschalek explains Financial times Viral vector vaccines direct the spike protein to the cell nucleus, rather than the cytosolic fluid in the cytoplasm.
Researchers believe this leads to protein cleavage and the creation of mutant copies that do not bind to the cell membrane where immunization usually takes place.
to me Research report Instead, the proteins will cause blood clots in some cases.
Problems arise in the cell nucleus
The Financial Times writes that mRNA vaccines, including Pfizer and Moderna, do not allow the spike protein to enter the cell nucleus.
“These viral genes can cause problems when they get into the nucleus,” Marshallk told the Financial Times.
We must be fully vaccinated under safe conditions
The professor thinks this problem can be solved if the vaccine developers can prevent the spike protein from dividing.
He also says Johnson & Johnson, which makes the Janssen vaccine, has already contacted the researchers and sought advice on how to modify the vaccine.
– They are now trying to improve the vaccine. With the information we have, we can tell companies how to prevent the protein from separating.
Warn
However, many caution that Marschalek’s theory is just one of many, and more evidence is needed to prove the validity of the research group’s theory.
However, Marshlik says he has provided the results to the state Paul Ehrlich Institute, as well as to the agency administering the German vaccination.
They were surprised by our findings, because no one previously thought the protein could be broken down, Marshlik says.
FHI: – That could be a good theory
FHI’s director of infection control, unlike Bokholm, says the results may be good news, but they need to be confirmed with more studies and more experimental data.
How likely are the results to be correct?
In theory, this could be a good theory.
– Theory: Bukholm says the findings in the report could theoretically be correct, but would not have major implications for Norway’s vaccination program. Photo: Stian Lysberg Solum / NTB
–
However, Bukholm does not think it appropriate to reintroduce AstraZeneca into the vaccination program, even if the vaccine could be modified.
It will likely take a long time to adapt, gain approval and get the vaccine back into production, these researchers suggest. At that time, we hope that the Norwegian population will be vaccinated.
For other reasons, vector vaccines will not be best suited as third and fourth dose vaccines, so they are unlikely to be reintroduced into the Norwegian program, the infection control manager continues.
–
